Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06708299 · ClinicalTrials.gov registry record · Phase 3
CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)
A Phase 3 study of Recurrent Pericarditis, sponsored by Cardiol Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 110
- Enrollment target
- 20
- Study locations
NCT06708299: Recruiting Phase 3 study of Recurrent Pericarditis, sponsored by Cardiol Therapeutics.
NCT06708299 is a Phase 3 study of Recurrent Pericarditis that is actively recruiting participants, run by Cardiol Therapeutics. The registered enrollment target is 110 participants, below the 199-participant average among 4 other Recurrent Pericarditis trials with a reported enrollment target (45% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06708299, a Phase 3 study of Recurrent Pericarditis, is actively recruiting participants, sponsored by Cardiol Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 110 participants
- Enrollment target
- 20
- Study locations
Study Summary
Multi-center, randomized, double-blind, placebo-controlled, phase-3 Trial. Patients with a history of recurrent pericarditis who are being treated with an IL-1 blocker for at least 12 months, scheduled to be discontinued, will be approached for potential trial participation. Double-blind treatment will be initiated 10 - 16 days prior to the last scheduled dose of the IL-1 blocker and continued for 24 weeks. The objective is to assess whether patients remain free of pericarditis recurrence while receiving CardiolRx.
Primary Outcome
proportions of patients free from a new episode of recurrent pericarditis\* from the timepoint of stopping the IL-1 blocker to Week 24
Conditions Studied
Interventions
- DRUG CardiolRx
Study Locations (20)
New York
- NYU Langone Health - New York
- Columbia University - New York Presbyterian - New York
- Columbia University - New York Presbyterian - New York
- Lenox Hill Hospital - New York
Florida
- Mayo Clinic Florida - Jacksonville
- Mayo Clinic - Jacksonville
Maryland
- Johns Hopkins University - Baltimore
- MedStar Health Institute - Columbia
Minnesota
- Minneapolis Heart Institute - Minneapolis
- Mayo Clinic - Rochester
Virginia
- University of Virginia - Charlottesville
- Virginia Commonwealth University - Richmond
Arizona
- Mayo Clionic Arizona - Phoenix
California
- UCI Health - Irvine
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2025-04-07 |
| Est. Completion | 2026-10-21 |
| Phase | Phase 3 |
What NCT06708299 shows while recruiting
NCT06708299 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 199-participant average among 4 other Recurrent Pericarditis trials with a reported enrollment target (45% lower).
The record links to 1 condition, with Recurrent Pericarditis appearing as the primary indexed condition, and to 1 intervention - of which CardiolRx is the first listed.
NCT06708299 names 20 study sites across 13 states, led by New York, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT06708299 about?
NCT06708299 is a clinical study titled "CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)". Multi-center, randomized, double-blind, placebo-controlled, phase-3 Trial. Patients with a history of recurrent pericarditis who are being treated with an IL-1 blocker for at least 12 months, scheduled to be discontinued, will be approached for potential trial participation. Double-blind treatment ...
What is the current status of trial NCT06708299?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 110 participants. The study started on 2025-04-07. Estimated completion is 2026-10-21.
What conditions does trial NCT06708299 study?
This clinical trial studies the following conditions: Recurrent Pericarditis.
What interventions are being tested in trial NCT06708299?
The interventions under investigation include: CardiolRx (DRUG).
Who is sponsoring clinical trial NCT06708299?
This trial is sponsored by Cardiol Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06708299 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Pericarditis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Transition to KPL-387 Monotherapy Dosing & Administration Study
RECRUITING · Phase 2
-
Phase 2/3 Study of KPL-387 in Recurrent Pericarditis
RECRUITING · Phase 2
-
An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis
RECRUITING · Phase 2
-
REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI